Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...
A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...
Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...
In the fourth quarter of 2024, Libtayo grew sales 50% to $367 million, propelling the PD-1 treatment past the blockbuster threshold for the first time. During the full year, the drug's sales reach ...
Libtayo may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) ...
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...
A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 versus Q4 2023. Approval in CSCC means that this growth catalyst is ...
LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback